Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 113 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Topical corticosteroid Clear all
Completed Phase 3 Interventional Results available

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 5, 2026, 10:52 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT05387707
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 5, 2026, 10:52 AM EDT
Not listed Phase 4 Interventional

Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue

NCT02398539
View directory record Official record
Conditions
Hypergranulation Tissue; Gastrostomy Tube Site
Interventions
Silver Nitrate, Triamcinolone
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery

NCT05023304
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical prednisolone acetate
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Topical Corticosteroid App

NCT02921503
View directory record Official record
Conditions
Topical Corticosteroid, Topical, Medication, Utilization
Interventions
mobile topical corticosteroid app
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 5, 2026, 10:52 AM EDT
Recruiting Phase 3 Interventional

Topical Cryotherapy and Keloid/Hypertrophic Scars

NCT07336368
View directory record Official record
Conditions
Keloid Scars, Hypertrophic Scars
Interventions
Cryotherapy with liquid nitrogen, Intralesional Triamcinolone 10 mg/ml
Device · Drug
Lead sponsor
Sonal Choudhary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Recruiting Not applicable Interventional

VALOR: Vaginal Atrophy & Long-term Observation of Recovery

NCT05953090
View directory record Official record
Conditions
Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva, Lichen Planus of Vulva, Lichen Simplex of Vulva (Disorder)
Interventions
7-0940
Device
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Burbank, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

NCT05436535
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

NCT00120523
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Topical corticosteroids
Drug
Lead sponsor
MEDA Pharma GmbH & Co. KG
Industry
Eligibility
3 Months to 12 Months
Enrollment
2,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 5, 2026, 10:52 AM EDT
Recruiting Not applicable Interventional

Vibratory Anesthesia on Pain Following Corticosteroid Injections

NCT07553273
View directory record Official record
Conditions
Bilateral Arthritis of Wrist, Tendinopathy, Arthropathy, Compression Neuropathy, Bilateral Arthritis of Hands
Interventions
Digivibe Device
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Recruiting Phase 3 Interventional

Parasitic Ulcer Treatment Trial

NCT06213649
View directory record Official record
Conditions
Acanthamoeba Keratitis
Interventions
Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo
Drug · Other
Lead sponsor
Jeremy Keenan, MD, MPH
Other
Eligibility
8 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 4 Interventional

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

NCT04708821
View directory record Official record
Conditions
Bilateral Conjunctivitis (Disorder)
Interventions
Dexamethasone ophthalmic insert 0.4Mg, 0.2% loteprednol etabonate ophthalmic suspension, olopatadine hydrochloride ophthalmic solution 0.7%
Drug
Lead sponsor
Clinical Research Center of Florida
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

NCT04183335
View directory record Official record
Conditions
Neurodermatitis
Interventions
Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 4 Interventional Results available

Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis

NCT01111123
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%), Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Xylitol for Chronic Sinusitis

NCT03229551
View directory record Official record
Conditions
Chronic Rhinosinusitis, Rhinosinusitis, Sinusitis, Drain Sinus, Endoscopic Sinus Surgery, Biofilms, Bacterial Overgrowth
Interventions
Xylitol, Saline
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 5, 2026, 10:52 AM EDT
Not listed Phase 2 Interventional

Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome

NCT01544283
View directory record Official record
Conditions
Shoulder Pain
Interventions
Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch, Triamcinolone Acetonide
Drug
Lead sponsor
Injury Care Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 5, 2026, 10:52 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 5, 2026, 10:52 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Pain Perception During Intra-Articular Knee Joint Injection: What is the Effect of Needle Gauge and the Use of Ethyl Chloride?

NCT06865170
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee, Fear of Needles
Interventions
25 gauge needle, 22 gauge needle, +/- Ethyl Chloride Topical Aerosol Anesthetic
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
40 Years to 89 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 4 Interventional Results available

Effect of Intraoperative Dexamethasone on Post-op Dry Eye

NCT04184999
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
dexamethasone intraocular suspension, 9%, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
SR Cornea Consultants
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Sycamore, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 5, 2026, 10:52 AM EDT
Active, not recruiting Phase 4 Interventional

Determination of the Optimal Treatment Target in Ulcerative Colitis

NCT04259138
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
Biological
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis

NCT01947491
View directory record Official record
Conditions
Psoriasis
Interventions
DFD01 Spray, Comp01 Lotion, Vehicle Lotion, Vehicle Spray
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
40
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Encinitas, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 5, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

NCT04202679
View directory record Official record
Conditions
Neurodermatitis
Interventions
Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Fort Smith, Arkansas • Sacramento, California • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 5, 2026, 10:52 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 5, 2026, 10:52 AM EDT